NCT02648048 - A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

Pirfenidone

Pirfenidone will be administered as per the dosage schedule mentioned in arm description.

DRUG

Vismodegib

Vismodegib will be administered as per the dosage schedule mentioned in arm description.

Trial Locations (15)

27403

Pulmonix LLC, Greensboro

28401

PMG Research of Wilmington, Wilmington

30625

Fraunhofer-Institut fur Toxikologie und Experimentelle Medizin ITEM, Hanover

32803

Central Florida Pulmonary Group, PA, Orlando

47303

Medical Consultants, PC ; Pulmonary, Muncie

60007

Suburban Lung Associates, Elk Grove

68131

Creighton University Medical Center, Omaha

70112

Tulane University Medical School, New Orleans

89503

Allied Clinical Research, Reno

92037

Scripps Clinic, La Jolla

98122

Swedish Medical Center, Seattle

98208

Western Washington Medical Group, Everett

40202-1798

University of Louisville, Louisville

02135

Steward St. Elizabeth's Medical Center ; Pulmonary, Critical Care and Sleep Medicine, Boston

07901

Atlantic Respiratory Institute, Summit

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY